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ABSTRACT
Psoriasis is a chronic skin disease that manifests as impaired epidermal differentiation.
The disease is typically treated with acitretin, an effective oral cytotoxic agent. However, due to
its side effects, its use is highly limited. Topical delivery of acitretin may decrease the systemic
toxicity and increase the drug’s bioavailability at the pathological site. However, this approach has
some limitations. The decrease in skin integrity due to psoriasis could lead to escape of drug into
the systemic circulation system and consequently compromise the topical approach. Also, the high
instability of acitretin in the presence of heat could limit its topical application. The aim of this
work is to formulate and characterize niosomes for topical delivery of acitretin in order to decrease
the drug’s systemic side effects, provide a controlled method of delivery to the pathological site,
and improve the thermal stability of acitretin. To achieve this goal, acitretin niosomes were
prepared using the thin film hydration technique. The niosomes were then characterized and
optimized for size, entrapment efficiency, and drug release. The characterized niosomes were
evaluated and investigated as a topical drug delivery system. The lead formulation displayed an
optimum particle size of 471±1.15 nm with a PDI of 0.4±0.04, zeta potential of -21±0.26,
entrapment efficiency of 92±2.70, and controlled drug release of 30.80±0.21 %. In vitro
permeation studies across a tab-stripped epidermis showed that niosomes can control the drug
permeation of compromised skin. The cumulative amount of drug permeated from niosomes was
1.87±0.09 µg/cm2, compared to 3.6±0.02 µg/cm2 with drug control and 2.4±0.08 µg/cm2 with
excipient control. Also, the in vitro deposition studies showed that the amount of the drug
deposited from niosomes to the epidermis after stratum corneum removal (665±0.2 ng/mg) was
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significantly greater than the amount of the drug in the solution and excipient control (385±0.1
and 205±0.4 ng/mg, respectively). Moreover, in vitro thermal degradation studies confirmed that
the acitretin niosome formulations have a longer half-life than the drug in solution (115.75 days
for samples stored at 4 ºC, 60.18 days for samples stored at 24 ºC, and 45.59 days for samples
stored at 40 ºC). In summary, the results showed that the incorporation of acitretin into niosomes
for topical delivery might be a promising approach for the treatment of psoriasis.
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PSORIASIS

Figure 1. Psoriatic skin

Disease overview

Psoriasis is a chronic skin disease that can result in substantial morbidity and mortality
(Rachakonda et al., 2014) (Armstrong et al., 2012) . The prevalence of psoriasis is about 3.2 %
among US adults aged 20 years and older (Gelfand et al., 2007). The disease is characterized by
the proliferation and keratinization of exaggerated and disordered epidermal cells as well as silvery
scales on the skin epidermis. Many efforts have been made to understand the pathophysiology of
disease. Unfortunately, the pathological sequence that causes keratinization has not yet been
identified. However, the most widely accepted hypothesis is that psoriasis is an immune-mediated
skin disease that affects genetically predisposed individuals who are exposed to triggering
environmental factors. The scales appear on the skin due to hyperproliferation of keratinocytes
and incomplete cornification and migration and accumulation of nuclei in the stratum corneum
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(SC) (Fig. 1). The mitotic rate of keratinocytes is much higher than that of normal cells, resulting
in thickening of the epidermis layer. This idea is supported by the efficacy of many immunemodulator agents for treatment of psoriasis. Psoriasis can manifest on any part of the body,
including the elbows, knees, and sacral regions, and produces sharp, dry, and itchy feelings
(Winterfield, Menter, Gordon, & Gottlieb, 2005) (Griffiths & Barker, 2007) (Langley, 2012).
These symptoms can affect patients’ quality of life both physically and psychologically (de Korte,
Mombers, Bos, & Sprangers, 2004) (Fig. 2).

Figure 2. Histology of normal and psoriatic skin

Management of psoriasis

The goal of psoriasis treatment is to decrease and suppress cutaneous lesions so that the
disease no longer affects patients’ employment and/or social life. The majority of patients cannot
achieve remission without treatment, so continuous therapy is required. The management of
psoriasis can be divided into three types of therapy: topical, photo, and systemic.
The management of psoriasis usually starts with topical treatment (Drake et al., 1993),
which is most useful in mild to moderate cases, when the disease covers less than 20 % of the
body’s surface area. Topical treatment is effective, convenient to use, and lacks the serious side
effects produced by other types of treatment. The most widely used topical treatment in the United
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States is corticosteroids (Wood, Greaves, & Weinstein, 1995), which have anti-inflammatory, antiproliferative, and immunosuppressive properties. More than 80 % of US dermatologists prefer to
prescribe topical corticosteroids for mild, limited psoriasis. The clinical efficacy of this drug is
highly related to its potency. A highly potent corticosteroid is highly anti-inflammatory, so it is
usually used for acute flare-ups of the disease, whereas medium-potent corticosteroids are used for
maintenance therapy (Liem, McCullough, & Weinstein, 1995). Despite the clinical effectiveness
of topical corticosteroids, their use may be accompanied by side effects, including local skin
atrophy, tachyphylaxis, fast relapse times, irritation from the vehicle, and contact dermatitis. Using
large amounts in cases of acute psoriasis can result in systemic absorption, leading to suppression
of the hypothalamic–pituitary–adrenal axis (Takeda, Arase, & Takahashi, 1988). Other topical
treatments include calcipotriene (a vitamin D analogue), tazarotene, coal tar, anthralins, and
keratolytics.
When psoriasis is extensive and severe, affecting more than 15–20 % of the body’s surface
area, topical treatment is impractical for management of disease. Frequent application of topical
agents over a large surface area is extremely costly and difficult for patients to perform. Thus,
severe cases of psoriasis should be treated using systemic medications. A systemic regiment is
often complicated and may require specialized equipment and continuous monitoring.
Patients with severe psoriasis flare-ups may also require phototherapy during
hospitalization. The Goeckerman regimen is a typical phototherapy regiment that involves twicedaily administration of ultraviolet B and coal tar. Once the condition is stabilized, systemic
treatment can be provided on a less frequent basis. The only three systemic medications for
psoriasis approved by the United States Food and Drug Administration (USFDA) are
methotrexate, cyclosporine, and acitretin.
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Many side effects are associated with systemic treatments. Long-term use of methotrexate
can cause toxicity, leading to bone marrow suppression, drug-induced hepatic fibrosis, or cirrhosis
(Roenigk et al., 1998). Administration of acitretin is also associated with a very high risk of
teratogenic effects. Because of its potential teratogenicity, acitretin should not be used by women
of child-bearing age (Gollnick et al., 1988). In addition, cyclosporine can cause severe
nephrotoxicity if used long term (ZACHARIAE, KRAGBALLE, HANSEN, MARCUSSEN, &
OLSEN, 1997). In a recent study, 34 of 122 (28 %) patients treated with cyclosporine for a period
of 22 months discontinued the treatment due to renal failure (Grossman et al., 1996). Of the three
systemic medications, acitretin is probably the safest for long-term treatment.

Acitretin
Acitretin is a free and active metabolite of etretinate, the first oral synthetic retinoid used
to treat psoriasis. Because of the superior pharmacokinetic properties of acitretin compared to
etretinate, the drug became the most widely used systemic retinoid (Orfanos, 1999). In fact, it is
the only systemic retinoid approved by the USFDA, and its effectiveness has been reviewed by
many researchers (Lee & Li, 2009).

Pharmacology of acitretin
Acitretin is available on the market as an oral capsule (10 and 25 mg). The bioavailability
of acitretin ranges between 20 and 90 % after oral administration. It requires 1–4 h to reach the
peak plasma level. It has much shorter half-life (2–4 days) than etretinate (120 days). Further,
acitretin is 50 times less lipophilic than etretinate, and because of that, its elimination time is much
shorter. Acitretin metabolizes to 13-cis-acitretin, and both are widely distributed throughout the
body. One month after discontinuing acitretin, the amount of the drug in plasma is undetectable.
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However, it can undergo re-esterification to produce etretinate, thereby increasing the risk of
teratogenicity. Acitretin’s mechanism of action is still unknown. However, it is believed that
acitretin induces and modulates the expression of growth factors in psoriatic epidermis and its
receptors. Overall, acitretin reduces the proliferation rate of psoriasis in the epidermis, promotes
differentiation between keratinocytes, regulates the desquamation of corneocyte, and decreases the
thickness of SC and inflammation in the epidermis and dermis.

Effectiveness of acitretin in psoriasis treatment
Acitretin has been found to be effective as a monotherapy for treating moderate to severe
psoriasis. Several studies were conducted to determine the efficacy of different dosages of acitretin
as a single agent for the treatment of different types of psoriasis. The efficacy of acitretin depends
on the clinical type of psoriasis. The drug showed good response to erythrodermic and pustular
psoriasis, However, acitretin exhibited moderate efficacy for treating chronic plaque-type psoriasis
(Goldfarb et al., 1988) (Olsen, Weed, Meyer, & Cobo, 1989).
Acitretin also was found to be effective as a combination therapy. When acitretin is used
in combination with calcipotriol, it can better clear psoriatic plaque (Rim, Park, Choe, & Youn,
2003). In a randomized paired comparison study, 60 % of patients achieved complete clearance of
psoriasis faster when treated with a combination of acitretin and calcipotriol. Moreover, the use of
acitretin combinations in photo(chemo)therapy improves the efficacy of such therapy and
decreases the UV dose and duration of treatment required for chronic plaque psoriasis (Saurat et
al., 1988) (Tanew, Guggenbichler, Hönigsmann, Geiger, & Fritsch, 1991).
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Side effects of acitretin
Acitretin is considered a pregnancy category X drug. Fetal abnormalities associated with
oral acitretin include meningomyelocele, meningoencephalocele, multiple bony malformations,
facial dysmorphia, low-set ears, high palate, anophthalmia, decreased cranial volume alterations,
abnormal appendages, hip malformations, multiple synostoses, and cardiovascular malformations.
Due to the serious teratogenic toxicity of acitrtin, psoriatic women of childbearing age are advised
to take an extensive course of birth control for at least three years after discontinuing psoriasis
therapy. Acitretin is also associated with mucocutaneous side effects like cheilitis, rhinitis, dry
mouth, pruritus, alopecia, and hair pigmentation. Moreover, it was reported that acitretin can cause
hyperlipidemia in 25–40 % of psoriatic patients (Katz, Waalen, & Leach, 1999). Generally, with
respect to teratogenicity, the adverse effects produced by acitretin are mild and reversible in nature,
and only a few cases might require discontinuation of the treatment.

Topical delivery of acitretin for the treatment of psoriasis
The current systemic therapies for psoriasis are highly limited by their side effects, as
mentioned above. Many psoriatic patients around the world have clearly indicated that they are
unsatisfied with their current treatment; in a survey conducted by the National Psoriatic
Foundation, only 28 % of patients were satisfied with their psoriasis therapy (McKenna & Stern,
1997). This low satisfaction occurs because the treatment is time-consuming and often ineffective
and systemic medications have adverse side effects.
During the search for safe and effective psoriasis treatment, interest in topical delivery
systems has increased. It is believed that topical systemic medications could inhibit the undesirable
side effects associated with conventional systemic treatment and increase the local availability of
the drug molecules at the target site. In addition, topical delivery helps avoid the first pass
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metabolism and offer continuous, controlled drug delivery. All of these advantages improve the
thermodynamic response and safety profile of drugs for treating psoriasis. Thus, a topical approach
to psoriasis treatment could be an ideal alternative to the conventional systemic approach.
Although topical drug delivery systems for treating psoriasis have many benefits, they are
still associated with many challenges, including the following: the variability in skin absorption
due to the application site, severity of disease, and patient’s age; the first pass metabolic effect on
skin; the reservoir capacity of the skin; and the potential for irritation and toxicity due to the drug.
Furthermore, targeting psoriatic tissue using a topical approach poses a big challenge due to the
fact that psoriatic skin is extremely dehydrated and thick, and thus usually has a lipid imbalance
and high sensitivity to irritants. Also, the lack of SC integrity in psoriatic skin could allow the drug
to escape into systemic circulation and consequently compromise topical delivery.
In addition to all the previous limitations of topical delivery for psoriasis treatment, topical
delivery of acitretin poses additional disadvantages. Acitretin induces skin sensitivity and is highly
unstable in the presence of air, heat, and light. Also, the drug has very low water solubility, which
makes it challenging to formulate topical acitretin. For topical delivery of acitretin to psoriatic
skin, the delivery vehicle must be suitably designed and developed to overcome all these
challenges.

Niosomes: a topical delivery system for acitretin
Niosomes are non-ionic surfactants formed by the hydration of a mixture of single-alkyl
chains of non-ionic surfactants and cholesterol, which results in a closed bilayer structure that was
first reported by Handjani-Vila et al. in 1979 (Agrawal, Petkar, & Sawant, 2010). Niosomes can
be produced using various types of non-ionic surfactants, including polyglycerol alkyl ethers,
crown ethers, ester-linked surfactants, glucosyldialkyl ethers, polyoxyethylene alkyl ethers, Brij,
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Tweens, and Spans. Niosomes have attracted a great deal of attention for their unique features,
which are suitable for dermal and transdermal delivery. For example, they are biodegradable,
biocompatible, and non-immunogenic. The vehicle is associated with better patient compliance
and better therapeutic effects than conventional oily formulations. They are capable of controlling
and sustaining the release of drugs due to depot formation. The shape, size, composition, and
fluidity of niosome formulation can be controlled when required (Haran, Cohen, Bar, & Barenholz,
1993). Also, niosomes can entrap large amounts of materials in a small volume of vesicles (Nasr,
Mansour, Mortada, & Elshamy, 2008). Interestingly, niosomes’ bilayer structure includes
hydrophobic tails, which are shielded from aqueous media, and hydrophilic head groups, which
have the most contact with aqueous media. This structure is similar to the phospholipid vesicle
structure of liposomes and is able to encapsulate both hydrophilic (in their inner spaces) and
hydrophobic drugs (in the lipid bilayer area) (raja, Pillai, Udupa, & Chandrashekar, 2017) (Fig. 3).
Niosomes can be considered an alternative to liposomes due to their ability to alleviate the
drawbacks associated with liposomes, such as chemical instability, variable purity of
phospholipids, and high cost. These features make niosomes an attractive option for topical
delivery of acitretin.

Figure 3. Arrangement of surfactants in niosomes
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Niosomes have been evaluated in several previous works as a topical delivery system for
psoriasis treatment. In a study done by M. Manconi et al., the efficacy of vesicular incorporation
of tretinoin for dermal delivery through pig skin was investigated. The results demonstrated that
niosomes have higher cutaneous drug retention than liposomes and commercial formulations and
that the cutaneous delivery of tretinoin is strongly affected by the vesicles’ composition and drug’s
thermodynamic activity (Mura, Pirot, Manconi, Falson, & Fadda, 2007).
In another study, the safety and efficacy of topical delivery of methotrexate via niosomes
were examined. The study aimed to assess irritation and sensitization among healthy human
volunteers caused by the prepared niosomal methotrexate compared to a placebo and marketed
methotrexate gel. The results showed that the niosomal methotrexate formulation more
significantly reduced (P<0.05) the total PASI score (from 6.7378±1.48576 to 2.0023±1.13718)
compared to a placebo and marketed methotrexate gel. The study concluded that the niosomal
methotrexate formulation is more effective than the placebo or marketed methotrexate gel
(Lakshmi, Devi, Bhaskaran, & Sacchidanand, n.d.).
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HYPOTHESIS AND SPECIFIC AIMS

We hypothesize that incorporating acitretin in a niosomal formulation improves the thermal
stability of the Active Pharmaceutical Ingredient (API) and result in controlled drug delivery at
the pathological site.

Aim 1. To obtain niosomes that have high API entrapment efficiency and are 200–600 nm in
size.
Different sonication and hydration times were initially applied to control the size and
entrapment efficiency of the prepared niosomes. The niosomes were characterized according to
size, PDI, zeta potential, and entrapment efficiency. Then, a second set of surfactants was
incorporated into the optimized formulation to achieve higher entrapment efficiency. The
resultant niosomes were characterized again according to size, PDI, zeta potential, and
entrapment efficiency.

Aim 2: To determine the optimum molar ratio of the lead surfactant, span 60, and cholesterol
for preparing acitretin-loaded niosomes.
Different molar ratios of the lead surfactant, span 60, and cholesterol were used to
prepare six niosome formulations and were characterized according to size, PDI, zeta potential,
entrapment efficiency, and drug release.
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Aim 3: To evaluate the lead niosome formulation as a topical delivery system of acitretin for
psoriasis treatment.
In vitro skin permeation and deposition studies were performed using intact and tapestripped porcine epidermis
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MATERIAL AND METHODS
Materials

Acitretin (98 %) was purchased from Pure Ontario Chemicals Inc., Canada. High
Performance Liquid Chromatography (HPLC)-grade solvents like methanol, ethanol, and
chloroform were purchased from Fisher Chemicals, USA. Span 60 and formic acid were purchased
from Sigma Chemicals, St. Louis, MO. Brij® 93 was gifted by BASF. Brij™ S100, Brij™ S20,
and Brij™ C10 were gifted by CRODA Inc., USA. Cholesterol was purchased from Alfa Aesar,
USA, and sephadex was purchased from MP Biochemicals, USA. Porcine skin was obtained from
Pontotoc Slaughterhouse, Pontotoc, MS, USA. Dialysis membrane (10 kDa) was purchased from
Spectrum Chemicals, New Brunswick, NJ, USA.

Methods
Development of niosomal formulations
Preparation of niosomes
Niosomes were prepared using the thin film hydration technique, for which sonication and
hydration time were already optimized. Accurate quantities of surfactants, cholesterol, and the
drug were obtained. The mixture was dissolved in an ethanol/chloroform solution (71.4:28.6 %)
in a round-bottom flask. The solvents evaporated at 60 °C under reduced pressure using a rotary
flash evaporator. After solvent evaporation, the flask was kept overnight in a vacuum evaporation
chamber to remove residual chloroform and ethanol. The resultant thin film was hydrated with 10
ml of phosphate buffer saline (PBS; pH 7.4), and the flask was rotated at 60 °C and 150 rpm for

12

30 min. The niosome formulations underwent probe sonication for 20 s three times with 20 s
intervals. The acitretin-entrapped vesicles were separated from the un-entrapped material using
gel chromatography of a sephadex G-50 column. The filtration process was repeated three times
before the filtered fraction was collected to ensure that there was no un-entrapped acitretin in the
filtrate. The niosomes were then collected in amber-colored vials and stored in a refrigerator at 58 ºC for future studies.

Effect of different sonication/hydration times on niosomes’ characteristics
At a fixed molar ratio of nonionic surfactant, span 60, and cholesterol, nine niosome
formulations were prepared using the thin film hydration technique as presented in Table 1.
Different hydration (10, 20, and 30 min) and sonication (0.5, 1, and 2 min) times were applied in
order to determine the best conditions for vesicle formation. Similar amounts of the drug (1 mg)
were loaded into the formulations. The niosome formulations were characterized according to size,
polydispersity index, zeta potential and entrapment efficiency.

Table 1. Design of the experiment investigating optimization of the thin film hydration method
Formulation
(F)

Sonication
Time (min)

Hydration Time
(min)

F1
F2
F3
F4
F5
F6
F7
F8
F9

0.5
1
2
0.5
1
2
0.5
1
2

10
20
30
20
30
10
30
10
20
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Span
60/Cholesterol
(molar ratio)
1:1
1:1
1:1
1:1
1:1
1:1
1:1
1:1
1:1

Drug Content
(mg)
1
1
1
1
1
1
1
1
1

Incorporation of secondary surfactant
Four niosome formulations were prepared using non-ionic surfactants (Brij c10, Brij s100,
Brij s20, and Brij 93) in combination with the non-ionic surfactant span 60 and cholesterol at a
molar ratio of 1:1:2. One mg of acitretin was loaded into all niosome formulations. The niosomes
was characterized according to size, PDI, zeta potential, and entrapment efficiency.

Variability studies
To study the effect of different molar ratios of surfactants to cholesterol on niosomes’
characteristics, six niosome formulations were prepared using our modified thin film hydration
method. The secondary lead surfactant (Brij 93) was mixed with span 60 and cholesterol at
different molar ratios, as presented in Table 2. Then, 1 mg of acitretin was loaded into all
formulations and niosomes were characterized according to size, PDI, zeta potential, entrapment
efficiency, and drug release.

Table 2. Design of variability studies
Formulation
(F)
F5-4A
F5-4B
F5-4C
F5-4D
F5-4E
F5-4F

Span 60
(molar ratio)
1
1
2
1
2
1

Brij 93
(molar ratio)
1
2
1
2
1
1
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Cholesterol
(molar ratio)
2
2
2
1
1
1

Drug Content
(mg)
1
1
1
1
1
1

Measurement of size, PDI, and zeta potential
Vesicle size and the distribution of prepared niosomes were measured by dynamic light
scattering (DLS) using a Zetasizer Nano ZS-90 instrument (Malvern Instruments, Worcestershire,
UK). Measurement was performed at a scattering angle of 90° after diluting and equilibrating the
suspension at 25 °C for 60 s. All measurements were performed in triplicate, and the results are
presented as the average value ± the standard deviation.

Measurement and calculation of entrapment efficiency
The entrapment efficiency, which is expressed as a percentage of the total amount of
acitretin encapsulated in niosomes, was determined using a centrifugation method. The prepared
niosomes were first filtered using Sephadex column G-50 to separate the entrapped drug from the
unentrapped drug. After that, we collected the filtered portion of niosomes and raptured the lipid
structure using Triton-X100 (0.01 % v/v) to extract the entrapped drug. Then, the niosomal
suspension was separated by centrifugation at 15,000 rpm for 15 min. Finally, the supernatant was
taken and quantified using HPLC. The same process was performed with the non-filtered niosomes
to obtain the unentrapped drug. Entrapment efficiency was calculated by comparing the entrapped
(filtered) and unentrapped (non-filtered) amounts of the drug using the following equation:
𝐸% =

𝐷𝑛𝑓 − 𝐷𝑓
𝑥100
𝐷
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In vitro release studies
An in vitro drug release study was carried out using a 250 ml glass beaker. A dialysis
membrane (10 kDa) was filled with 0.5 ml of niosome formulations and immersed in 200 ml of
ethanol/PBS (20:80) receiver medium. The temperature of the dispersion medium was maintained
at 25 °C with magnetic stirring at 300 rpm throughout the experiment. A sample volume of 1 ml
was taken from the receiver medium at different time points during the 12 h experiment and
replaced with the same amount of fresh medium to maintain the conditions. The samples were
analyzed and quantified using HPLC.

In vitro permeation studies
A fresh porcine skin was brought from a local slaughterhouse. The abdominal skin regions
were taken and shaved using an electric shaver. The hairless skin was cut into small rectangular
pieces. Then, the pieces were covered with aluminum foil and immersed in a water bath maintained
at 60 ºC for 2 min. After 2 min, the aluminum foil was removed and the epidermis was carefully
mounted by hand on clean glass slides. Then, the epidermis was kept for 12 h until it was
completely dried and then was stored in a refrigerator at 5 ºC for future use. The in vitro skin
permeation study was performed using Franz diffusion cells with an effective diffusion area of
0.64 cm2. A hairless porcine epidermis was sandwiched between the donor and receiver medium
with the SC side facing the donor compartment. The receiver compartment was filled with 5 ml of
an ethanol/PBS solution (20:80), maintained at 37 °C, and continuously stirred throughout the
experiment. Then, 0.5 ml of niosome suspension was loaded into the donor compartment. Acitretin
and excipient solutions were used as controls. One ml samples were withdrawn from the receiver
medium at different time points and replaced by equal quantities of fresh medium. The amount of
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acitretin in these samples was quantified and determined using HPLC. During the 24 h experiment,
the donor and receiver media were covered with aluminum foil to prevent light exposure. The
cumulative amount of drug permeated over time was plotted and compared with the drug and
excipient controls.

In vitro skin deposition studies
A skin deposition study was performed to estimate the amount of drug retained in the
epidermis. At the end of the permeation study, the epidermis was carefully removed from the
diffusion cells and washed with a water/methanol solution 3 times to remove excess formulations
remaining on the top layer. The epidermis was kept for 6 hours until it was completely dry. The
diffusion area was cut using a tube-puncturing cutter and accurately weighed. Next, 1 ml of NaOH
(0.1 N) was added to the epidermis, which was then kept overnight in a rotary shaker until
completely dissolved. Then, 1 ml of acetonitrile was added to the dissolved epidermis in order to
extract the retained drug. The mixture was kept in a rotary shaker for 6 h until phase separation
clearly appeared. The upper phase, which contains the drug, was removed and centrifuged for 15
min at 15,000 rpm. The supernatant was then removed and the drug content was determined using
HPLC.

HPLC analysis
An isocratic HPLC method was developed for quantifying acitretin. The experiment was
performed using a water HPLC system (Water 600 Controller, USA) equipped with a 600 pump
unit, a 717 plus autosampler with an injection valve with a sample loop of 50 µl, and a 2487 dual
absorbance UV detector. The mobile phase consists of 0.01 % acetonitrile/formic acid solution
(90:10 v/v) and was delivered at a flow rate of 1 ml/min-1. Then, 20 µl of the injection was eluted
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in a LUNA 54, C18, 4.6×150 mm column (Phenomonex, USA) at room temperature. The column
eluent was monitored at 360 nm, and the acitretin peaks were separated at a retention time of 5
min.

Stability studies
Physical stability studies were carried out to investigate the leaking of acitretin from
niosomes and the thermal stability of niosomal acitretin. Niosome formulations were sealed in 10
ml amber-colored glass vials and stored at three different temperatures (5 ºC, 25 ºC, and 37 ºC) for
a period of 90 days. Samples from each patch were taken at time points of 0, 30, and 90 days. The
niosomes’ drug content, size, PDI, and zeta potential were measured and compared.
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DEVELOPMENT AND OPTIMIZATION OF NIOSOME FORMULATIONS

Results
The effect of different sonication/hydration times on niosomes’ characteristics

Table 3. Characterization of niosomal formulations
Formulation
(F)
F1
F2
F3
F4
F5
F6
F7
F8
F9

Entrapment
Efficiency
(EE %)
36±0.10
39±9.21
57±2.24
81±5.50
72±2.10
18±1.02
87±2.01
27±10.31
13±9.03

Particle Size
(nm)
800±0.01
405±3.20
184±1.01
756±1.02
397±0.10
220±1.21
812±1.03
519±3.01
200±1.03

Polydispersity
Index
(PDI)
1.00±0.01
0.61±0.03
0.80±0.01
0.58±0.04
0.58±0.03
0.43±0.01
0.66±0.20
1.00±0.04
0.80±0.01

Zeta Potential
(mV)
-16.00±0.15
-9.33±0.58
-5.00±0.65
-4.33±0.57
-13.33±0.57
-5.67±1.52
-12.17±0.29
-3.67±0.58
-4.33±0.58

The effect of different sonication times on niosomes’ characteristics
Sonication time is an important variable during the preparation of niosomes. It can
influence the size, PDI, and entrapment efficiency of niosomes. Proper sonication time can lead to
less variation in vesicles’ size and hence less particle aggregation. We used different sonication
times (0.5, 1, and 2 min) to determine their effect on the entrapment efficiency of niosomes. The
results of these trials demonstrated that sonication time had a significant effect (P<0.05) on
entrapment efficiency. As presented in Table 3, high average entrapment efficiency was obtained
for niosome formulations sonicated for 0.5 min (68±0.15 %), while medium average entrapment
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efficiency was obtained for niosomes sonicated for 1 min (46±0.30 %) and low average entrapment
efficiency was obtained for niosomes sonicated for 2 min (29±1.01 %). Also, the results showed
that sonication time significantly affected the size of niosomes (P<0.05). The average size of
niosomes sonicated for 0.5 min was 789± 1.01 nm, compared to 440± 0.01 nm for those sonicated
for 1 min and 272± 0.03 nm for those sonicated for 2 min. Sonication time was found to have no

% ENTRAPEMENT EFFICIENCY

significant effect on PDI (P>0.05).
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Figure 4. The entrapment efficiency of niosome formulations, obtained by applying different
sonication times (0.5, 1 and 2 min)

The effect of different hydration times on niosomes’ characteristics
Hydration time is another important factor in the formation of niosomes. Improper
hydration time can result in the formation of fragile niosomes or leakage problems. To determine
the optimal hydration time, several were applied. The results showed that high average entrapment
efficiency was obtained for niosome formulations hydrated for 30 min (72±2.24 %), medium
average entrapment efficiency was obtained for niosomes hydrated for 20 min (44±1.03 %), and
very low average entrapment efficiency was obtained for niosomes hydrated for 10 min (27±1.02
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%) (Table 3). The results of this study did not show that hydration time had a significant effect on

% ENTRAPEMENT EFFICIENCY

the niosomes’ size, PDI, or zeta potential (p>0.05).
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Figure 5. The entrapment efficiency of niosome formulations, obtained by applying different
hydration times (10, 20, and 30 min)

Effect of incorporating a secondary surfactant on the characterized formulation
The main goal of incorporating a second surfactant into a niosome formulation (F5) is to
further improve the entrapment efficiency of the system. Adding another surfactant may create a
synergistic effect that could form niosomes with high entrapment efficiency. From a
pharmaceutical viewpoint, entrapment efficiency is one of the most important factors affecting
niosome formulations. Niosomes with high entrapment efficiency require less time and effort to
remove unentrapped material during manufacturing. Additionally, during topical delivery, high
niosome entrapment efficiency allows more API to be permeated and localized within the skin. To
achieve this goal, four different nonionic surfactants were chosen based on their hydrophiliclipophilic balance (HLB) to be incorporated into a previously characterized formulation (F5)
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(Table 4). The results showed that, among the four surfactants, Brij 93 produced the highest
entrapment efficiency. The entrapment efficiency of niosomes formed using Brij 93 as a secondary
surfactant was 90± 0.03 %, compared to 30±0.12 % for those formed with Brij c10, 13±1.01 % for
those formed with Brij s100, and 20±0.10 % for those formed with Brij s20.

Table 4. Characterization of niosome formulations with secondary surfactants
Formulation
(F)

Type of
surfactant

(HLB)
Value

Size
(nm)

F5-1
F5-2
F5-3
F5-4

Brij C10
Brij S100
Brij S20
Brij 93

12
18
15
4

30±0.12
13±1.01
20±0.10
90±0.03

Polydispersity
index
(PDI)
353±1.29
279±0.65
312±1.54
420±0.35

Zeta
Potential
(mV)
0.65±0.54
0.7±0.05
0.3±0.04
0.5±0.05

Entrapment
Efficiency
(EE%)
-19±0.65
-21±1.51
-11±0.54
-18±0.75

Discussion
One of the most commonly used laboratory methods for niosome preparation and drug
loading identified in the literature is the thin film hydration method. This method was previously
described by Bangham et al. (1965) for the preparation of liposomes. However, this method
requires further vesicle optimization for topical delivery of acitretin. Our aim was to obtain high
API entrapment efficiency and a vesicle size of 200–600 nm. It was reported that a smaller particle
size (≤200 nm) will easily permeate skin, especially psoriatic skin, where the SC lacks integrity,
and enter into systemic circulation. This is not favorable for our purpose. In addition, it was
reported that a larger particle size (≥600 nm) will not permeate the SC barrier (Verma, Verma,
Blume, & Fahr, 2003). Thus, we believe that niosomes sized between 200 and 600 nm will help
us achieve our aim.
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To achieve our aim, different sonication (0.5. 1 and 2 min) and hydration (10, 20 and 30
min) times were applied to determine the effect of these parameters on the niosomes’
characteristics. We found a negative relationship between sonication time and entrapment
efficiency; as we increased the sonication time, entrapment efficiency decreased (Fig. 6). The
highest entrapment efficiency was obtained with niosome formulations F4, F5, and F7. However,
F4 and F7 were excluded because of their high average size (>600 nm). The optimum formulation
in terms of sonication time was F5, which was sonicated for 1 min. Hydration time, on the other
hand, was positively related to the entrapment efficiency of niosome formulations (Fig. 5). The
highest entrapment efficiency was obtained with niosome formulations F5 and F7. However, F7
was excluded because of its size (>600 nm). The optimum formulation in terms of hydration time
was F5, which was hydrated for 30 min, perhaps because new vesicles form during long hydration
times. The hydration medium and time highly influence the self-assembly of non-ionic surfactants.
Increasing the hydration time during self-assembly formation of niosomes will allow more vesicles

% ENTRAPMENT EFFICIENCY

that can accommodate more API to be formed.
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Figure 6. The entrapment efficiency of niosome formulations prepared using different HLB
value surfactants
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Also, a negative relationship was found between entrapment efficiency and the HLB values
of the second surfactants (Fig. 4). The highest entrapment efficiency was obtained for niosomes
prepared using surfactants with low HLB values, and vice versa. A low HLB value indicates a
long hydrocarbon chain compared to hydrophilic surface area. A long hydrocarbon chain will
increase the lipophilic character of surfactants. Surfactants with low HLB values, like Brij 93, have
a more lipophilic environment to accommodate lipophilic drugs like acitretin (log p= 6.4).

Conclusion
To sum up, the thin film hydration method with 1 min sonication time and 30 min
hydration time was found to create the optimum niosome formulation (F5). The nonionic
surfactant Brij 93 (HLB=4) is used as a lead secondary surfactant to form niosomes with the
highest entrapment efficiency (F5-4).
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VARIABILITY STUDIES OF THE CHARACTERIZED NIOSOMES

Results
The effect of various molar ratios of surfactants to cholesterol on niosomes’ characteristics
After we determined the optimum surfactants for topical niosome formulations, we aimed
to identify the optimal molar ratio of surfactants to cholesterol for obtaining the lead niosome
formulation. We have conducted this set of experiments to determine the effect of various molar
ratios of the lead secondary surfactant Brij 93, span 60, and cholesterol on niosomes’ size, PDI,
zeta potential, entrapment efficiency, and drug release.

Table 5. Characterization of niosomes and effect of various molar ratios of surfactants to
cholesterol
Formulation
(F)

Size
(nm)

Polydispersity
index (PDI)

F5-4A
F5-4B
F5-4C
F5-4D
F5-4E
F5-4F

471±1.15
549±1.06
463±1.75
361±1.03
364±2.21
404±1.71

0.41±0.04
0.80±0.10
0.58±0.09
0.58±0.02
0.43±0.02
0.66±0.09
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Zeta
Potential
(mV)
-21±0.26
-17±1.37
-20±0.61
-12±0.61
-13±1.31
-15±0.72

Entrapment
Efficiency
(EE%)
92±2.70
83±0.69
81±1.30
64±3.19
68±2.27
71±21.14

Drug Release
(%)
30.80±0.21
46.72±1.16
40.17±1.10
64.70±0.53
70.00±0.64
81.12±1.61

The effect of the lead secondary surfactant Brij 93 and span 60 on niosomes’ characteristics
Using different molar ratios of span 60 to Brij 93 had no significant effect (P>0.05) on
niosomes’ characteristics. Maintaining the levels of cholesterol and Brij 93 and changing the level
of span 60 showed no significant differences in the size, PDI, zeta potential, entrapment efficiency,
or drug release of niosomes, nor did maintaining the levels of span 60 and cholesterol and changing
the level of Brij 93 (Tables 2 and 5).

% CUMULATIVE RELEASE

100
F5-4A

80

F5-4B

60

F5-4C

40

F5-4D

20

F5-4E

0

F5-4F
0

2

4

6
Time(h)

8

10

12

Figure 7. In vitro drug release of various formulations of acitretin niosomes

The effect of cholesterol on niosomes’ characteristics
Using different molar ratios of cholesterol had no significant effect (P>0.05) on the size,
PDI, or zeta potential of niosome formulations. Maintaining the levels of span 60 and Brij 93 and
changing the level of cholesterol showed no significant difference in the size, PDI, or zeta potential
of niosomes (Table 2 and 5). However, entrapment efficiency was significantly influenced by
changing the cholesterol level in niosome formulations (P<0.05). The average entrapment
efficiency of niosome formulations F5-4D, F5-4E, and F5-4F (cholesterol=molar ratio of 1) was
low (64±3.19, 68±2.27, and 71±1.14 %, respectively). However, high average entrapment
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efficiency (92±2.70, 83±0.69 and 81±1.30 %, respectively) was obtained for niosome formulations
F5-4A, F5-4B, and F5-4C (cholesterol=2 molar ratio) (Fig. 8). Moreover, the in vitro release
studies of formulations revealed that using different molar ratios of cholesterol had a significant
effect (P<0.05) on niosomes’ drug release. Formulations prepared using low concentrations of
cholesterol (F5-4D, F5-4E, and F5-4F) resulted in faster drug release (64±0.53, 70±0.64, and
81±1.61 %, respectively). However, the other formulations prepared using higher concentrations
of cholesterol (F5-4A, F5-4B, and F5-4C) achieved slower and more controlled drug release

% ENTRAPMENT EFFICIENCY

(30±0.21, 46±1.16, and 40±1.10 %, respectively) (Fig. 9).
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Figure 8. The average entrapment efficiency of niosome formulations F5-4A, F5-4B, and F5-4C
(cholesterol=molar ratio of 1) compared to niosome formulations F5-4D, F5-4E, and F5-4F
(cholesterol=molar ratio of 2)
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Figure 9. In vitro drug release of niosome formulations with molar ratio of 1 for cholesterol
compared to formulations with a molar ratio of 2 for cholesterol at the same surfactant
concentration

Discussion
Cholesterol has an important impact on niosomes’ entrapment efficiency and drug release.
Cholesterol influences the physical properties and structure of niosomes through its interaction
with nonionic surfactants. It can affect formulations by modulating the cohesion, mechanical
strength, and water permeability of the lipid bilayer. In fact, inclusion of cholesterol into niosome
formulations could increase the viscosity and rigidity of the bilayer structure. Drug partitioning in
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the lipid bilayer will be easier with a highly structured system of surfactants and cholesterol. By
using more cholesterol, the lipid bilayer will become more rigid and, consequently, more drugs
will be encapsulated within the bilayer structure and will be less likely to escape. This may explain
the high entrapment efficiency and slow drug release of niosome formulations containing more
cholesterol. The best entrapment efficiency and drug release were obtained for niosome
formulation F5-4A, which was prepared with a 1:1:2 molar ratio of span 60, Brij 93, and
cholesterol, respectively.

Conclusion
In conclusion, 1:1:2 is the optimum molar ratio of span 60, Brij 93, and cholesterol,
respectively, for preparing niosomes for controlled topical delivery of acitretin. The lead niosome
formulation was F5-4A.
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LEAD NIOSOMAL FORMULATION STABILITY STUDIES

Results
Stability studies of vesicular size, PDI, and zeta potential
During a 90-day stability study, the results showed that at all temperatures (4 ºC, 24 ºC,
and 40 ºC), the niosome formulations showed no significant changes in size, PDI, or zeta potential
(P<0.05) (Fig. 10). After 90 days, the average niosome sizes were 458±0.13, 465±0.43, and
471±0.34 nm at 4 ºC, 24 ºC, and 40 º C, respectively, compared to 425±1.04 nm at day 0. Also,
the niosomes’ PDIs were 0.51±0.01, 0.54±0.03, and 0.56±0.03 at 4 ºC, 24 ºC, and 40 ºC,
respectively, compared to 0.42±0.03 at day 0. Finally, the niosomes’ zeta potentials were -11±0.32,
-10±0.31, and -9±0.43 mV at 4 ºC, 24 ºC, and 40 ºC, respectively, compared to -21±0.51 mV at
day 0.

Stability studies of niosomes’ drug content
Ninety-day drug content stability studies were performed to study the drug release from
the lead niosome formulation. The results showed non-significant drug release from niosomes over
90 days at all temperatures (P>0.05) (Fig. 11). After 90 days, the percentages of drug retained in
the niosomes were 88±0.14 %, 86±0.32 %, and 82±0.21 % at 4 ºC, 24 ºC, and 40 ºC, respectively,
compared to 100 % at day 0.
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Figure 10. The size, PDI, and zeta potential of the best noisome formulation stored at different
temperatures (4 °C, 24 °C, and 40 °C) for 0, 30, and 90 days
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Figure 11. The drug content of the lead niosome formulation stored at different temperatures
(4 °C, 24 °C, and 40 °C) for 0, 30, and 90 days
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In vitro thermal degradation studies
In vitro thermal degradation studies were performed to study and compare the thermal
degradation of acitretin in solution with respect to the lead niosome formulation. The results
showed less degradation of acitretin in the niosome formulation compared to acitretin in solution
(Table 6). With the niosome formulation, the drug’s half-life was 501.51, 429.87, and 334.34 days
at 4 ºC, 24 ºC, and 40 ºC, respectively, compared to 115.75, 60.81, and 45.59 days at 4 ºC, 24 ºC,
and 40 ºC, respectively, for acitretin in solution.

Table 6. In vitro thermal degradation studies of acitretin niosome formulation versus acitretin in
solution
Acitretin Drug
Formulation
Acitretin Niosome
Formulation

4 ºC

Half-Life (Days)
24 ºC

40 ºC

501.51

429.87

334.34
45.59

Acitretin in
Solution

115.75

60.18

Discussion
The stability data demonstrates that the lead niosome formulation has good physical
stability. Over a period of 90 days, there was no sign of vesicle aggregation in niosome samples
stored at different temperatures. The high negative zeta potential indicates the stability of the
colloidal system. If all the particles in the suspension have a high negative zeta potential, then they
will tend to repel each other and there will be no chance for them to come together. Also, the data
from these studies revealed that the lead niosome formulation has good chemical and thermal
stability. The niosomes showed good ability to reduce the thermal degradation of acitretin. The

32

highly arranged bilayer structure of niosomes could play an important role in protecting the drug
molecule from degradation as it might provide a cooler environment for the drug than the outside
environment.

Conclusion
Highly physically, chemically, and thermally stable niosomes can be prepared using Brij
93, span 60, and cholesterol with a molar ratio of 1:1:2, respectively. After a period of 90 days,
the prepared niosomes had low particle aggregation, drug release, and degradation.
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EVALUATION OF LEAD NIOSOME FORMULATION USING ACITRETIN AS A
TOPICAL DELIVERY SYSTEM

Results
In vitro skin permeation studies across intact porcine epidermis
In order to study the influence of niosome formulations on acitretin diffusion through the
skin, we carried out an in vitro permeation study using a porcine epidermis and Franz diffusion
cells. During this study, we compared the permeation data obtained from niosomal acitretin with
those obtained from the drug and excipient controls. Fig. 12 shows the permeation profile
(cumulative amount of acitretin permeated versus time) of acitretin through the epidermis obtained
from niosomes in comparison with controls. The niosomes showed improvement in cumulative
drug percutaneous permeation (0.14±0.01 µg/cm2) compared to that of the drug control (0.03±0.02
µg/cm2) and the excipient control (0.04±0.01 µg/cm2). The flux rate was 0.004±0.01 ng/cm2/h for
the niosome formulation, 0.0007 ±0.02 ng/ cm2/h for the drug control, and 0.001±0.03 ng/cm2/h
for the excipient control.
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Figure 12. Cumulative amount of acitretin permeated from best niosome formulation (F5-4A)
across a porcine epidermis
In vitro skin deposition studies using intact porcine epidermis
At the end of the permeation studies, the epidermis was removed and the amount of drug
retained was measured to assess the skin deposition capability of niosomes. The results showed
that the drug deposition of niosomes was significantly higher than that of the controls (Fig. 13).
The amount of drug deposited within the epidermis was 230±01.02 ng/mg with niosomes,
compared to 46±0.02 ng/mg with the drug control and 84±02.01 ng/mg with the excipient control.

In vitro skin permeation studies across tab-stripped porcine epidermis
The previous permeation studies were performed using an intact epidermis. However, in
cases of psoriasis, the SC might be compromised, so to better assess the permeability of our lead
niosome formulation, we carried out a permeation study with an epidermis after SC was removed
in order to simulate real psoriatic skin conditions. The results showed that the niosomes were able
to control the permeation of the drug across damaged skin (Fig. 14). The skin permeability of

35

niosomes was 1.87±0.09 µg/cm2, compared to 3.6±0.02 µg/cm2 for the drug control and 2.4±0.08
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Figure 13. In vitro skin deposition study of acitretin-loaded best niosome formulation (F5-4A)
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Figure 14. In vitro permeation study of best niosome formulation with acitretin (F5-4A)
compared to drug and excipient controls across tab-stripped porcine epidermis
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In vitro skin deposition studies using tab-stripped porcine epidermis
We also performed a skin deposition study using an epidermis with tab-stripped SC in
order to obtain accurate information about the ability of niosomes to deposit acitretin within a
psoriatic epidermis. Again, the niosomes showed a significant improvement in the deposition of
acitretin in skin compared to the controls (P<0.05) (fig. 15). The amount of drug retained within
epidermis was 665±0.02 ng/mg for the niosomes, compared to 385±0.01 ng/mg for the drug
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Figure 15. In vitro skin deposition study of best niosome formulation with acitretin (F5-4A)
compared to drug and excipient controls within a tab-stripped porcine epidermis

Discussion
The higher permeability of niosomes across an intact epidermis compared to the controls
might be due to the role of the nonionic surfactant span 60; it was reported that span 60 enhances
skin permeation (J.-Y. Fang, Yu, Wu, Huang, & Tsai, 2001). Many mechanisms have been
proposed to explain the ability of niosomes to modulate drug transfer across skin in order to
understand niosomes’ enhanced skin permeability (Uchegbu & Vyas, 1998) (J. Fang, Hong, Chiu,
& Wang, 2001) (Vora, Khopade, & Jain, 1998). However, the most interesting mechanism is
vesicles’ ability to fuse on the surface of skin, which might lead to the accumulation of large
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concentration gradients of intercalated drug within the skin layer and therefore increase permeation
(Schreier & Bouwstra, 1994). However, when the epidermis is compromised, niosomes control
topical acitretin permeation, which is considered to be an advantage of a topical approach to
psoriasis treatment.
One of the main reasons to employ niosomes for topical delivery of acitretin was its dermal
localization, which enhances the localized treatment of psoriasis and reduces its systemic toxicity.
For this purpose, in vitro skin deposition of niosomes was investigated using intact and
compromised porcine epidermises, and the results from these experiments revealed significant
drug deposition in the epidermis with niosomes compared to the controls (P<0.05) (Figs. 13 and
15). The results from these studies supported the hypothesis that incorporating acitretin into
niosomes enhances drug deposition into skin epidermis. The results are also in agreement with
several previous studies reporting that niosomes improve the dermal localization of several topical
therapeutic agents (Abdelbary & Aboughaly, 2015) (Manconi, Sinico, Valenti, Lai, & Fadda,
2006) (Goyal et al., 2015).

Conclusion
In the current work, topical application of acitretin-loaded niosomes for management of
psoriasis was investigated to avoid systemic toxicity. The lead niosomal formulation displayed an
optimum particle size and high entrapment efficiency. Also, the in vitro thermal degradation
studies confirmed that niosomes can induce the thermal stability of acitretin. Moreover, the in vitro
skin permeation and deposition studies suggested that niosomes can control the topical delivery of
acitretin and improve the drug localization at the skin pathological site. In conclusion, the results
confirmed that acitretin niosomes may have profound therapeutic application in a topical approach
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to the treatment of psoriasis. However, further studies and investigations using a suitable animal
model are required in order to establish the superiority and safety of the developed niosomes
compared to the current systemic acitretin therapy.
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